盐酸安罗替尼治疗晚期非小细胞肺癌的效果观察

Clinical effect of anlotinib hydrochloride on advanced non-small cell lung cancer

目的分析盐酸安罗替尼治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法抽取2019年1月至2021年5月郑州大学附属洛阳中心医院收治的晚期NSCLC患者78例,以随机数字表法分为研究组与对照组,每组39例。对照组采用单纯三线化疗方案(多西他赛),研究组在对照组基础上加用盐酸安罗替尼三线治疗。比较两组临床效果、血气指标、肿瘤标志物水平、卡氏评分(KPS)、肺癌患者生存质量测定量表评分(FACT-L)及不良反应发生率。结果研究组疾病控制率、总有效率分别为87.18%(34/39)、51.28%(20/39),均高于对照组的43.59%(17/39)、12.82%(5/39),P均<0.05。治疗后,研究组动脉血氧饱和度高于对照组,动脉血二氧化碳分压低于对照组(P<0.05);治疗后,研究组癌胚抗原、角蛋白19片段抗原21-1、糖类抗原125、糖类抗原199水平均低于对照组(P均<0.05);治疗后,研究组KPS、FACT-L评分均高于对照组(P均<0.05);两组腹泻、恶心呕吐、口腔黏膜炎发生率比较差异未见统计学意义(P>0.05)。结论晚期NSCLC患者采用盐酸安罗替尼治疗可提高治疗效果,改善患者血气水平、下调肿瘤标志物表达,安全性良好,可改善机体状况和生活质量。

Objective To analyze the clinical effect of androtinib hydrochloride in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 78 patients with advanced NSCLC treated in Luoyang Central Hospital Affiliated to Zhengzhou University from January 2019 to May 2021 were selected,and they were divided into study group and control group according to random number table method,with 39 cases in each group.The control group was treated with third-line chemotherapy alone(docetaxel),and the study group was treated with third-line treatment of androtinib hydrochloride based on the treatment of the control group.Clinical effect,blood gas index,tumor marker level,Karnofsky Performance status scale score(KPS),quality of life scale score of lung cancer patients(FACT-L)and incidence of adverse reactions were compared between the two groups.Results The disease control rate and total effective rate of the study group were 87.18%(34/39)and 51.28%(20/39),respectively,which were higher than 43.59%(17/39)and 12.82%(5/39)of the control group(all P<0.05).After treatment,arterial oxygen saturation in the study group was higher than that in the control group,while arterial partial pressure of carbon dioxide was lower than that in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen,keratin 19 fragment antigen 21-1,carbohydrate antigen 125 and carbohydrate antigen 199 in the study group were lower than those in the control group(all P<0.05).After treatment,KPS and FACT-L scores in the study group were higher than those in the control group(all P<0.05).There was no significant difference in the incidence of diarrhea,nausea and vomiting and oral mucositis between the two groups(P>0.05).Conclusions The treatment of advanced NSCLC patients with antiotinib hydrochloride can improve the therapeutic effect,improve blood gas level,down-regulate the expression of tumor markers,with good safety,and improve the body condition and quality of life.